African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
Search
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
A Unique Bond: human and animal health
A Unique Bond: human and animal health
A Few Ways We Support US Livestock | Boehringer Ingelheim US
Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.
Facing Lung Cancer: Keith’s Story
Facing Lung Cancer: Keith’s Story
Scam alert
Scam alert
Koropi
With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
Why today’s depression trials demand smart new approaches
Why today’s depression trials demand smart new approaches
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.
Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business
Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
BI Cares PAP portal
BI Cares PAP portal
Sophia Malki: A Woman on the Rise
Sophia Malki: A Woman on the Rise
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Financial year 2018
Financial year 2018